pharma · Breast Cancer · Multiple Sclerosis (MS)
HOFFMANN-LA ROCHE
Hoffmann-La Roche
Hoffmann-La Roche is a pharma organization headquartered in Basel, CH. Primary therapeutic focus areas include Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumo
Company details
- Status
- Public
- HQ
- Mississauga, Ontario L5N 5M8, CA
- Employees
- 10
- Programs
- 286
- Drugs
- 212
- Patents
- 0
WP43295
Phase 1 · other · BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with or without Central Nervous System Metastases
WP43295 for BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with or without Central Nervous System Metastases is a Phase 1 program (other) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Internal code WP43295
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Hoffmann-La Roche
- Phase
- Phase 1
- Modality
- other
- Indication
- BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with or without Central Nervous System Metastases
- Status
- active
- Trials
- 1